FOLD: Amicus Therapeutics, Inc.
About
Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Current Value
$9.491 Year Return
Current Value
$9.491 Year Return
Key Details
Market Cap
$2.84B
P/E Ratio
-27.29
1Y Stock Return
-11.52%
1Y Revenue Growth
32.58%
Dividend Yield
0.00%
Price to Book
15.9
Strategies that include FOLD
Stock's related to FOLD
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNLI | 45.61% | $3.50B | +33.66% | 0.00% |
| ALDX | 44.63% | $294.18M | +102.46% | 0.00% |
| KYMR | 42.64% | $2.77B | +125.95% | 0.00% |
| BEAM | 42.01% | $2.09B | -9.52% | 0.00% |
| RCKT | 42.01% | $1.20B | -39.83% | 0.00% |
| ABCL | 41.20% | $800.44M | -37.56% | 0.00% |
| PGEN | 41.14% | $228.91M | -28.00% | 0.00% |
| SDGR | 40.96% | $1.38B | -35.46% | 0.00% |
| RXRX | 40.89% | $1.80B | -4.13% | 0.00% |
| ZYME | 40.75% | $1.03B | +79.68% | 0.00% |
| FIBK | 40.74% | $3.49B | +33.95% | 5.62% |
| FLGT | 40.74% | $519.98M | -37.82% | 0.00% |
| BPMC | 40.60% | $6.01B | +42.68% | 0.00% |
| VSAT | 40.48% | $876.93M | -65.78% | 0.00% |
| KWR | 40.45% | $2.91B | -5.30% | 1.14% |
| TY | 40.24% | - | - | 3.32% |
| ALLO | 39.97% | $444.50M | -24.82% | 0.00% |
| KALV | 39.94% | $440.88M | +17.08% | 0.00% |
| CLNE | 39.87% | $589.93M | -23.92% | 0.00% |
| RCEL | 39.84% | $321.96M | +27.43% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SCKT | -0.14% | $10.88M | +15.32% | 0.00% |
| WM | -0.21% | $87.92B | +27.58% | 1.34% |
| FATBB | 0.22% | $81.94M | -12.91% | 11.69% |
| OCFT | -0.26% | $80.95M | -30.38% | 0.00% |
| OCX | -0.28% | $42.93M | -36.09% | 0.00% |
| GRAL | 0.29% | $459.22M | -13.00% | 0.00% |
| CCEC | 0.34% | $1.02B | +28.03% | 3.26% |
| CXW | -0.35% | $2.43B | +62.08% | 0.00% |
| OXBR | -0.35% | $19.05M | +178.18% | 0.00% |
| SOC | -0.36% | $1.93B | +74.70% | 0.00% |
| IMRN | -0.36% | $10.31M | -5.04% | 0.00% |
| CBOE | 0.41% | $21.46B | +15.84% | 1.11% |
| SRG | 0.43% | $221.13M | -55.94% | 0.00% |
| APRE | -0.46% | $16.41M | -19.47% | 0.00% |
| TPST | 0.49% | $37.75M | -77.59% | 0.00% |
| ACGL | -0.54% | $36.00B | +16.84% | 0.00% |
| XOS | 0.56% | $30.51M | -57.24% | 0.00% |
| PSEC | 0.57% | - | - | 15.48% |
| CARV | 0.64% | $8.48M | -8.79% | 0.00% |
| EDSA | 0.65% | $7.11M | -21.79% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| MCK | -23.63% | $78.15B | +35.51% | 0.42% |
| TCTM | -16.28% | $8.10M | -42.99% | 0.00% |
| LITB | -14.38% | $35.48M | -75.45% | 0.00% |
| MOH | -12.11% | $16.16B | -21.56% | 0.00% |
| PRPO | -11.85% | $9.10M | -13.65% | 0.00% |
| MNST | -10.60% | $52.25B | -1.95% | 0.00% |
| TEM | -9.72% | $8.50B | 0.00% | 0.00% |
| CME | -9.54% | $82.76B | +9.21% | 1.98% |
| SW | -9.23% | $13.78B | +15.02% | 1.14% |
| NEUE | -8.20% | $40.93M | -34.13% | 0.00% |
| BROS | -8.08% | $5.67B | +74.77% | 0.00% |
| STG | -8.04% | $35.67M | +7.92% | 0.00% |
| HUSA | -7.70% | $16.69M | -11.56% | 0.00% |
| PULM | -7.16% | $19.83M | +202.98% | 0.00% |
| COR | -7.06% | $47.48B | +21.20% | 0.86% |
| QTTB | -6.72% | $354.34M | +188.64% | 0.00% |
| VERX | -6.35% | $7.99B | +89.70% | 0.00% |
| CYD | -6.08% | $364.46M | -2.94% | 4.26% |
| ARLP | -5.33% | $3.54B | +26.77% | 10.11% |
| BTCT | -5.04% | $42.61M | +353.33% | 0.00% |
ETF's related to FOLD
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| PDBC | -0.08% | $4.40B | 0.59% |
| BSCO | 0.16% | $2.35B | 0.1% |
| GSG | 0.28% | $914.42M | 0.75% |
| GBIL | -0.67% | $5.60B | 0.12% |
| COMT | 0.95% | $829.06M | 0.48% |
| DBO | -1.13% | $217.57M | 0.77% |
| MINT | -1.29% | $11.62B | 0.35% |
| AGZD | -1.54% | $142.76M | 0.23% |
| USCI | 1.69% | $185.47M | 1.07% |
| DBC | 1.71% | $1.39B | 0.87% |
| DBE | -1.75% | $50.13M | 0.77% |
| SHV | 1.77% | $18.13B | 0.15% |
| SGOV | -1.82% | $27.53B | 0.09% |
| TPMN | 2.05% | $40.60M | 0.65% |
| DBA | -2.11% | $755.88M | 0.93% |
| IBTE | 2.16% | $1.70B | 0.07% |
| UNG | 2.32% | $908.80M | 1.06% |
| TBIL | -2.39% | $4.38B | 0.15% |
| KRBN | -2.55% | $242.47M | 0.85% |
| XHLF | 2.56% | $874.27M | 0.03% |
News
Yahoo
HALO vs. FOLD: Which Stock Is the Better Value Option?
Yahoo
Amicus Therapeutics ( NASDAQ:FOLD ) Third Quarter 2024 Results Key Financial Results Revenue: US$141.5m (up 37% from 3Q...
Yahoo
Amicus Therapeutics Inc (FOLD) reports a 37% revenue increase and raises full-year guidance, despite ongoing litigation challenges.
Yahoo
Q3 2024 Amicus Therapeutics Inc Earnings Call
Yahoo
The headline numbers for Amicus Therapeutics (FOLD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Yahoo
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 25% and 5.68%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.